Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enlonstobart - CSPC Pharmaceutical Group/Hangzhou Sumgen Biotech

Next Previous
X
Search
Drug Profile

Enlonstobart - CSPC Pharmaceutical Group/Hangzhou Sumgen Biotech

Alternative Names: Enshuxing; Recombinant human anti-PD-1 monoclonal antibody - CSPC Pharmaceutical Group/Hangzhou Sumgen Biotech; SG-001; SYSA-1802

Latest Information Update: 09 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hangzhou Sumgen Biotech
  • Developer CSPC Pharmaceutical Group; CSPC ZhongQi Pharmaceutical Technology; Hangzhou Sumgen Biotech
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cervical cancer
  • Phase II Colorectal cancer
  • Phase I Solid tumours
  • Discontinued Biliary cancer

Most Recent Events

  • 31 Jul 2024 Phase I development is ongoing for Solid tumours (Late-stage disease) in China (IV) (CTR20190222) (NCT03852823)
  • 28 Jun 2024 Launched for Cervical cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV) - First global launch
  • 28 Jun 2024 Pooled efficacy analysis from a phase Ib and phase II trial in Cervical cancer was released by CSPC Pharmaceutical Group

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top